Skip to main content
editorial
. 2018 Oct 11;61(20):9059–9061. doi: 10.1021/acs.jmedchem.8b01405

Figure 1.

Figure 1

Clinical candidate ABX-1431 is a monoacylglycerol lipase (MGLL) inhibitor that prevents the hydrolysis of the endocannabinoid 2-arachidonoylglycerol in the human brain. It prolongs the action of 2-arachidonoylglycerol on the cannabinoid CB1 and CB2 receptors and reduces the formation of arachidonic acid, the substrate of proinflammatory prostanoids, thereby alleviating neurological symptoms and reducing neuroinflammation.